BPC-157 Dosing and Pharmacokinetics
Research-context only. All dosing data from preclinical studies and human pilot literature.
All dosing information on this page derives from published preclinical studies and small human pilot reports. This is not dosing guidance for any human or animal clinical application. BPC-157 is not approved for human use by any regulatory agency.
Pharmacokinetics
A 2022 formal PK study in Sprague-Dawley rats and beagle dogs documented BPC-157 pharmacokinetics across IV and intramuscular routes. [11]
| Parameter | Rat (IV) | Rat (IM) | Dog (IV) | Dog (IM) |
|---|---|---|---|---|
| Elimination half-life | <30 min | <30 min | <30 min | <30 min |
| Cmax timing | — | 3–9 min | — | 3–9 min |
| IM Bioavailability | — | 14–19% | — | 45–51% |
| Dose-linearity | Confirmed | Confirmed | Confirmed | Confirmed |
| IV dose tested | 20 μg/kg | — | 6 μg/kg | — |
| IM dose ladder | — | 20/100/500 μg/kg | — | 6/30/150 μg/kg |
| Primary excretion | Urine & bile via rapid peptide fragmentation | |||
| Highest tissue conc. | Kidney, liver, stomach (post-IV) | |||
Plasma concentration vs. time schematic: sharp Cmax at 3–9 minutes post-IM injection; exponential decay to baseline within 30 minutes. Despite this rapid clearance, tissue repair effects persist to day 14–90 in published studies.
Despite the short systemic half-life, in vivo efficacy in tissue-repair models persists well beyond plasma clearance — possibly via rapid receptor engagement triggering downstream gene expression cascades that outlast the peptide's plasma presence. This dissociation between PK and PD has been noted in the 2025 Pharmaceuticals review. [20]
Gastric stability is a distinct property: BPC-157 survives the acidic and peptic gastric environment without a protective carrier, enabling per-oral delivery. This property distinguishes it from most therapeutic peptides, which require parenteral-only dosing. It is attributed to the peptide's derivation from the gastric cytoprotective protein.
Research Doses by Study Type
The following dose ranges appear in the peer-reviewed preclinical literature. These are study-context parameters; they are not dosing recommendations for any purpose.
Intraperitoneal injection (rodent models — most common route)
Standard dose ladder: 10 μg/kg, 10 ng/kg, 10 pg/kg. Multiple studies show efficacy across this picogram-to-microgram range. Used in: tendon, [1] ligament, [3] wound, [4] muscle, [5] angiogenesis, [7][8][12][13] and neurological models. [9][10]
Oral administration (drinking water or gavage)
10 μg/kg/day and 10 ng/kg/day in drinking water (approximately 0.16 μg/mL, 12 mL/rat/day). Used in: ligament healing, [3] muscle-to-bone reattachment, [18] vascular occlusion. [8] Oral per-oral delivery produced results comparable to IP in multiple studies — consistent with gastric acid stability.
Topical cream
1 μg/g, applied daily. Used in: wound healing, [4] muscle crush injury, [5] ligament healing. [3]
High-dose toxicology reference
No toxic dose established up to 20 mg/kg in rats and 10 mg/kg in dogs across toxicology studies surveyed in the 2025 patent and literature review. [20]
Human pilot doses (not preclinical)
Administration Routes in Research Context
Nine routes across the published literature: green = parenteral systemic routes, amber = oral/topical routes, blue = human pilot routes.
Nine distinct routes appear across the published literature for BPC-157:
| # | Route | Context | Bioavailability |
|---|---|---|---|
| 1 | Intraperitoneal (IP) | Standard rodent research; no human equivalent | — |
| 2 | Subcutaneous (SC) | Hypertension-reperfusion study [12] | — |
| 3 | Intramuscular (IM) | Formal PK characterization [11] | 14–19% (rat), 45–51% (dog) |
| 4 | Intravenous (IV) | PK studies; human safety pilot [11][14] | 100% (by definition) |
| 5 | Oral gavage | Rodent research via gavage syringe | Not formally quantified |
| 6 | Oral in drinking water | Ad libitum per-oral; efficacy comparable to IP in matched studies [3][18] | Not formally quantified |
| 7 | Topical cream (1 μg/g) | Direct application to wound or injured tissue surface [3][4][5] | — |
| 8 | Local injection | Direct injection into bone defect in rabbit model [6] | — |
| 9 | Intravesical instillation | 10 mg injected into bladder; human IC pilot [15] | — |
Half-Life and Sustained Efficacy: A Note on PK-PD Dissociation
The plasma elimination half-life of less than 30 minutes raises a pharmacologically interesting question: how does a peptide with a sub-30-minute half-life produce tissue repair effects that were measured at day 14, day 28, and day 90 in published studies?
The preclinical literature points to rapid receptor engagement — particularly via the VEGFR2 pathway — triggering downstream transcriptional cascades (VEGF upregulation, CD34 expression, FAK-paxillin activation) that continue well after BPC-157 has been cleared systemically. [7][17] In this model, BPC-157 functions more like an initiating signal than a sustained mediator.
This pharmacokinetic-pharmacodynamic dissociation is characteristic of several peptide-based compounds studied in tissue repair contexts. The 2025 Pharmaceuticals review [20] identifies the short half-life as a key formulation consideration — a factor driving the ten active patents documented in that review for combination therapies and novel delivery systems.
The practical implication for research study design is that once-daily dosing regimens (as used in most published studies) may not reflect continuous systemic exposure. Whether the rapid signal-initiation model fully explains the sustained healing effects, or whether gastric stability and local tissue retention contribute independently, remains an open research question.